OMX Copenhagen PI
1.184,85
PKT
+20,97
PKT
+1,80
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 09.01.23 | Novo Nordisk Sell | UBS AG | |
| 05.01.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 03.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.12.22 | Novo Nordisk Overweight | Barclays Capital | |
| 15.12.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 13.12.22 | A.P. Moeller - Maersk A-S (B) Hold | Deutsche Bank AG | |
| 12.12.22 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 07.12.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 25.11.22 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 14.11.22 | Novo Nordisk Overweight | Barclays Capital | |
| 08.11.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.11.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 03.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 02.11.22 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 02.11.22 | Novo Nordisk Sell | UBS AG | |
| 02.11.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 07.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.10.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 21.09.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.09.22 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 23.08.22 | Novo Nordisk Sell | UBS AG | |
| 22.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 17.08.22 | Novo Nordisk Sell | UBS AG | |
| 15.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 05.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.08.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.08.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 04.08.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 04.08.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. |